james_edin said:The FLOW trial results on renal function and renal outcomes: semaglutide 1.0mg reduced the composite kidney outcome by 24% (HR 0.76, p=0.0003) in CKD…
Mine went the same way, slower. The detail I would add is minor and it is already implied above.
DoseLogDan said:Kidney function labs on renal function — good news for anyone concerned about renal effects: Marker Baseline Month 6 Ref Range eGFR 87 94 >60…
This matches mine closely enough to be worth saying so out loud.
DoseLogDan said:Kidney function labs on renal function — good news for anyone concerned about renal effects: Marker Baseline Month 6 Ref Range eGFR 87 94 >60…
There is a second half to this that has not been said yet. Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak. People who dose late are not losing a peak, they are letting the trough fall, and the appetite effect tracks the trough.
Correct me if the detail matters more than I have assumed.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsThe figures, for anyone assembling their own picture. Worth knowing that the injection site changes very little. Abdomen, thigh and upper arm are bioequivalent for semaglutide, so a site change is not a plausible explanation for a bad week.
Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. No action needed from anybody.